Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Growth in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 122,300 shares, a growth of 35.4% from the December 15th total of 90,300 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 169,400 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Investors Weigh In On Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd increased its position in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,660 shares of the company’s stock after purchasing an additional 36,441 shares during the period. XTX Topco Ltd owned approximately 0.13% of Achilles Therapeutics worth $42,000 as of its most recent filing with the Securities and Exchange Commission. 56.38% of the stock is currently owned by institutional investors and hedge funds.

Achilles Therapeutics Trading Down 0.9 %

ACHL stock opened at $1.15 on Friday. Achilles Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.76. The firm has a market capitalization of $47.27 million, a PE ratio of -0.70 and a beta of 1.32. The business’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $0.94.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.